Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NMBR | P28336 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312957 | 0.86 | SIRT2 (0.41) | SIRT2ALDH1A1 | |
| SCHEMBL1312709 | 0.84 | SIRT2 (0.39) | SIRT2NMBRENPP2 | |
| SCHEMBL10457235 | 0.79 | SIRT2 (0.37) | SIRT2ENPP2 | |
| SCHEMBL5060964 | 0.79 | LMNA (0.40) | SIRT2ENPP2 | |
| SCHEMBL9518110 | 0.78 | FLT3 (0.39) | SIRT2KDM4EALDH1A1ENPP2 | |
| SCHEMBL1736246 | 0.77 | CYP11B1 (0.37) | SIRT2ENPP2 | |
| SCHEMBL31646315 | 0.76 | CYP11B1 (0.38) | SIRT2ENPP2 | |
| SCHEMBL6363934 | 0.75 | SIRT2 (0.38) | SIRT2NMBRENPP2 | |
| SCHEMBL3959113 | 0.75 | SIRT2 (0.40) | SIRT2NMBRCYP2C19HIF1A | |
| SCHEMBL4499763 | 0.75 | SIRT2 (0.38) | SIRT2KDM4EALDH1A1NMBRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7629472-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20070276143-A1 | Method for producing optically active compound | YAMANO TORU | 2007-11-29 | — | — | US | disclosed |
| EP-1489070-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7247732-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060229457-A1 | Method for producing optically active compound | YAMANO TORU | 2006-10-12 | — | — | US | disclosed |
| US-7084278-B2 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050107433-A1 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276143-A1 | Method for producing optically active compound | CYP8B1, HRH3, HRH1 | SIRT2 1128/4885KDM4E 4092/4885ALDH1A1 544/4885 |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | SIRT2 4327/4885KDM4E 1502/4885ALDH1A1 319/4885 |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | SIRT2 3756/4885KDM4E 1183/4885ALDH1A1 1252/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | SIRT2 4096/4885KDM4E 900/4885ALDH1A1 198/4885 |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | CYP17A1, HSD17B7, HSD17B1 | SIRT2 3753/4885KDM4E 1184/4885ALDH1A1 1246/4885 |
| US-20060229457-A1 | Method for producing optically active compound | CYP8B1, HSD11B1, HSD17B7 | SIRT2 1117/4885KDM4E 4217/4885ALDH1A1 526/4885 |
| US-20050107433-A1 | Process for production of optically active compounds | CYP8B1, HSD11B1, CYP51A1 | SIRT2 1689/4885KDM4E 3830/4885ALDH1A1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.